Assuming that the decrease in IL-6 is due to SBI and given that higher IL-6 levels are associated with increased atherosclerosis and cardiovascular disease [33, 34], AIDS events [35], non-AIDS events [36], and mortality [2, 34, 37], an intervention that decreases its levels could have a profound impact on clinical outcomes in HIV infection. The gene discussed is IL6; the disease is atherosclerosis.